

## ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 2, 2011 (GLOBE NEWSWIRE) -- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Company management will present at two investor conferences in the coming weeks.

- **2011 Credit Suisse Healthcare Conference**  
9:00 am MST/11:00 am EST on November 11, 2011 in Phoenix, AZ  
Presenter: Daniel Junius, President and CEO
- **Lazard Capital Markets' 8<sup>th</sup> Annual Healthcare Conference**  
11:30 am EST on November 15, 2011 in New York, NY  
Presenter: Daniel Junius, President and CEO

The webcast of each presentation can be accessed live through the "Investor Information" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay of each presentation will be available at the same location for one week.

### About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

CONTACT: For Investors:

Carol Hausner  
Executive Director,  
Investor Relations and Corporate Communications  
ImmunoGen, Inc.  
(781) 895-0600  
[info@immunogen.com](mailto:info@immunogen.com)

For Media:

Barbara Yates  
The Yates Network  
(781) 258-6153